Together, these data outline a role for the tumor-intrinsic NLRP3 inflammasome in driving acquired resistance to checkpoint inhibitor immunotherapy by triggering the recruitment of an immunosuppressive population of PMN-MDSCs. This evidence concerns the gene NLRP3 and neoplasm.